Early safety check: how a drug acts in damaged livers
NCT ID NCT07250633
Summary
This early-stage study aims to understand how a single dose of the drug vorasidenib is processed by the body in people with severe liver impairment compared to people with normal liver function. It will involve 20 participants who will be closely monitored for safety and have their blood levels of the drug measured. The main goal is to gather data on how the drug behaves in these different groups to inform future research.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.